Investors might want to bet on Intensity Therapeutics Inc. (INTS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund 10.69k Oct 31, 2025 0.02% 4,350 Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund 6.92k Oct 31, 2025 0.01% 2,815 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Which players have recorded the most defensive interceptions in a single NFL season? You'll find that list here. Keep up with the 2025 NFL season on FOX Sports. Check out FOX Sports for more NFL Stats ...

The AWS SDK for Java enables Java developers to easily work with Amazon Web Services and build scalable solutions with Amazon S3, Amazon DynamoDB, Amazon Glacier, and more. See the AWS SDK for Java ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Get all the key statistics for Intensity Therapeutics, Inc. (INTS), including valuation measures, fiscal year financial statistics, trading records, share statistics and more.